-
MAO-B inhibitor
Quercetin inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C. -
MAO-B inhibitor
Quercetin inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C.- Sumayyah Saeed, .et al. , Int J Mol Sci, 2025, Jan 14;26(2):654 PMID: 39859369
-
MAO Inhibitor
Safinamide Mesylate is mesylate salt of Safinamide, which selectively and reversibly inhibits MAO-B with IC50 of 0.45 μM. -
MAO B inhibitor
Rasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B). -
Monoamine oxidase inhibitor
Rasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen. -
MAO Inhibitor
Moclobemide is a reversible and selective inhibitor of monoamine oxidase A (MAO-A).- Linyu Cao, .et al. , Eur J Pharmacol, 2020, Jun 5;876:173058 PMID: 32131022
-
MAO-A inhibitor
Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor. -
MAO-B inhibitor
Safinamide is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. -
MAO Inhibitor
Bifemelane hydrochloride is an antidepressant MAO inhibitor. Reverses catalepsy induced by tetrabenazine in mice and increases locomotor activity in MPTP-treated marmosets. -
LSD1/BHC110 & MAO inhibitor
Tranylcypromine hydrochloride is a non-selective MAO-A/B inhibitor. -
MAO inhibitor
Olodaterol is a long acting beta-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD), manufactured by Boehringer-Ingelheim. -
alpha-adrenergic receptor agonist / MAO inhibitor
Amitraz, also known as Mitaban and Taktic, is an alpha-adrenergic receptor agonist and MAO inhibitor used as an insecticide in prevention of flea and tick infections. It prevents prostaglandin synthesis and may inhibit beta-cell insulin release. -
MAO inhibitor
Pargyline hydrochloride is an irreversible inhibitor of monoamine oxidase (MAO) that is used clinically to treat moderate hypertension. -
monoamine oxidase A inhibitor
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline. - Harmaline is a psychoactive indole found naturally in certain plants. Its stimulating activities are achieved, in part, through inhibition of monoamine oxidases, thus increasing the levels of monoamine neurotransmitters (e.g., at 7-70 μM/kg in rats). Harmaline (30 mg/kg) induces tremor in mice through the N-methyl-D-aspartate (NMDA) receptor, at which harmaline may act as an inverse agonist.
-
MAO inhibitor
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor (MAOI) that is used as an antidepressive agent. -
MAO inhibitor
Molindone HCl is a D2 dopamine receptor antagonist. It also acts as a MAO inhibitor. -
monoamine oxidase inhibitor
Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro. -
MAO-A inhibitor
Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAOA) inhibitor. Antidepressant. -
MAO inhibitor
Iproniazid phosphate is an irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity. -
LSD1/MAO-B inhibitor
Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor. -
LOXL2 inhibitor
PAT-1251 is a potent, selective and oral Lysyl Oxidase-Like 2 (LOXL2) inhibitor. -
MAO-B inhibitor
Lazabemide(Ro 19-6327) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively). -
MAO-B inhibitor
(S)-Rasagiline (TVP1022) is the S-isomer of Rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor. -
Monoamine oxidase inhibitor
Rasagiline 13C3 mesylate racemic is the deuterium labeled Rasagiline, which is an irreversible inhibitor of monoamine oxidase. -
inhibitor of monoamine oxidase-A (MAO-A)
Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A). -
MAO inhibitor
Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC50 of 0.2?μM for MAO-A. -
MAO inhibitor
(S)-Rasagiline (TVP1022) mesylate is the S-isomer of rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor. -
LOXL2 inhibitor
PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively). -
MAO/LSD1 Inhibitor
Tranylcypromine hemisulfate is an irreversible, nonselective inhibitor of monoamine oxidase (MAO) and also acts as a lysine-specific demethylase 1 (LSD1) inhibitor. This compound demonstrates notable antidepressant effects and is utilized in the treatment of depression. Additionally, tranylcypromine hemisulfate has been shown to suppress lesion growth and alleviate generalized hyperalgesia in mouse models of induced endometriosis, making it a valuable tool for research in both psychiatric and pain-related studies. -
hMAO-A Inhibitor
Osthenol is a reversible and selective competitive inhibitor of human monoamine oxidase A (hMAO-A), with an IC50 of 0.74 μM and a Ki of 0.26 μM. This compound exhibits both antifungal and antibacterial properties, while also modulating the oxidative deamination of monoamine neurotransmitters. Additionally, Osthenol has been shown to inhibit the PI3K/AKT signaling pathway, leading to apoptosis in colon cancer cells, G1 phase cell cycle arrest, and reduced cell proliferation. Its applications are significant in the study of neurological disorders and cancer, particularly in targeting MAO-A for depression and investigating mechanisms in colon cancer. -
MAO-A/B Inhibitor
1,4-Naphthoquinone serves as a potent inhibitor targeting monoamine oxidase A and B (MAO-A/B) with competitive inhibition of MAO-B (Ki=1.4 μM) and non-competitive inhibition of MAO-A (Ki=7.7 μM). This compound exhibits broad-spectrum biological activity, inhibiting various DNA polymerases alongside notable anti-tumor, anti-inflammatory, and antibacterial properties. Its mechanism includes the induction of oxidative stress, glutathione (GSH) depletion, suppression of DNA synthesis, and blockage of NF-κB nuclear translocation. 1,4-Naphthoquinone is applicable in research involving melanoma and colon cancer cell growth, endothelial cell function, and models of lipopolysaccharide (LPS)-induced inflammation. -
HDAC1/MAO-B Inhibitor
HDAC1/MAO-B-IN-1 is a selective inhibitor targeting both HDAC1 and MAO-B, exhibiting IC50 values of 21.4 nM and 99.0 nM, respectively. This compound effectively crosses the blood-brain barrier, making it a valuable tool for studying neurological disorders. Its potential applications include research into Alzheimer's disease and related pathologies, facilitating the exploration of epigenetic modifications and monoamine metabolism in the brain. -
MAO A/HDAC Inhibitor
MAO A/HDAC-IN-1 is a dual inhibitor targeting monoamine oxidase A (MAO A) and histone deacetylases (HDAC). This compound exhibits significant biological activity in glioma research, facilitating studies on tumor biology and epigenetic modifications. Additionally, MAO A/HDAC-IN-1 features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a valuable tool for click chemistry applications in investigating cellular processes. -
LSD1/HDAC6/MAO-A Inhibitor
LSD1/HDAC6-IN-2 is a potent inhibitor targeting LSD1, HDAC6, and MAO-A, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. It demonstrates significant inhibitory effects on the growth of multiple myeloma cell lines, including MM.1S, MM.1R, and RPMI-8226. This compound is suitable for research applications focused on acute myeloid leukemia and lymphoma, providing insights into potential therapeutic mechanisms. -
HDAC6/MAO-A/LSD1 Inhibitor
HDAC6-IN-3 is a potent inhibitor of histone deacetylase 6 (HDAC6), with an IC50 ranging from 0.02 to 1.54 μM for various HDAC isoforms, including HDAC1, HDAC2, HDAC3, and HDAC8. Additionally, it exhibits significant inhibitory activity against monoamine oxidase A (MAO-A) with an IC50 of 0.79 μM and lysine-specific demethylase 1 (LSD1). This compound serves as a valuable tool for research applications in cancer biology and epigenetics and is equipped with an alkyne functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
Ferroptosis/MAO-B Inhibitor
MAO-B-IN-45 is a selective inhibitor of MAO-B with an IC50 of 87.47 nM, demonstrating over 229-fold selectivity for MAO-B compared to MAO-A. This compound exhibits significant antiferroptosis activity by modulating the iron metabolic pathway and the glutathione peroxidase 4 (GPX4) axis in vitro. Research indicates that MAO-B-IN-45 enhances cognitive and behavioral functions in 3×Tg (APP/Tau/Ps1) Alzheimer's disease mouse models, while also reducing levels of ferritin heavy chain 1 (FTH1), amyloid precursor protein (APP), and phosphorylated Tau (p-Tau) in the brain. -
Monoamine Oxidase Inhibitor
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC50 value of 3 μM, making it a valuable tool in neuropharmacological research. In addition to its MAO inhibitory activity, isatin also interacts with central benzodiazepine receptors (IC50 against clonazepam, 123 μM) and acts as an antagonist of both atrial natriuretic peptide-stimulated and nitric oxide-stimulated guanylate cyclase activity. This compound's multiple mechanisms of action highlight its potential in studying the serotonergic system and its related pathways in various biological contexts. -
MAO Inhibitor
Phenelzine sulfate is an irreversible, orally active monoamine oxidase (MAO-A and MAO-B) inhibitor, primarily utilized as an antidepressant agent. It enhances levels of neurotransmitters, including serotonin, norepinephrine, and dopamine, while inhibiting GABA transaminase and primary amine oxidase, and sequestering reactive aldehydes. Additionally, Phenelzine sulfate suppresses oxidative stress and lipogenesis and inhibits LSD1 (Ki: 5.6 μM). Its applications extend across research into neurological, metabolic, and oncological diseases, particularly in the context of depression, anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson's disease, Alzheimer's disease, inflammatory pain, obesity, and prostate cancer. -
MAO Inhibitor
Tranylcypromine-d5 hydrochloride is a deuterium-labeled derivative of the irreversible, nonselective monoamine oxidase (MAO) inhibitor, Tranylcypromine. It exhibits potent antidepressant activity by inhibiting MAO, thereby increasing levels of neurotransmitters such as serotonin and norepinephrine in the brain. Additionally, this compound has been identified as a lysine-specific demethylase 1 (LSD1) inhibitor, demonstrating efficacy in reducing lesion growth and alleviating generalized hyperalgesia in mouse models of induced endometriosis. It serves as a valuable tool in neurological and pain research applications.

